UVB-induced Treg Cells Exert Antigen-specific Suppression Through LAG-3

NCT05636839 | Unknown

• 1 other identifier: 202112019RINA
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to compare the immune cell population in blood of the participants with psoriasis/atopic dermatitis before and after UVB treatment. The main questions it aims to answer are:

1. 1.how immune cells in the PBMCs from blood of participants are affected by UVB treatment
2. 2.will UVB treatment expand the antigen-specific Treg cell population
3. 3.will UVB treatment enhance the suppressive function of Treg cells

Conditions

Psoriasis; Atopic Dermatitis

Keywords

UVB treatment; antigen specificity; regulatory T cell; mass cytometry

Outcome Measures

Primary Outcomes (1)

• Change in the percentage of Treg cells

  Change from baseline in Treg cell percentage in the peripheral blood of psoriasis patients treated with UVB

  10 weeks

Study Arms (1)

UVB treatment

EXPERIMENTAL

UVB treatment 3 times per week for 10 weeks Before treatment starts, researchers will collect 20 ml of blood from participants. After 10-week treatment, researchers will collect 20 ml of blood from participants again.

Radiation: UVB treatment

Interventions

UVB treatment RADIATION

UVB treatment 3 times per week for 10 weeks

UVB treatment

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At least 20 years of age
• Able and willing to provide written informed consent

You may not qualify if:

• UV exposure in the last 8 weeks before study entry
• Patients with contraindications for UV-treatment
• History of cancer and primary immunodeficiency
• pregnant or nursing mother
• participating in another clinical trial

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospital

Taipei, 100, Taiwan

RECRUITING

MeSH Terms

Conditions

Psoriasis; Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Yungling Lee, Dr

  Academia Sinica, Taiwan

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Tsen-Fang Tsai, MD

CONTACT

+886-23123456; tftsai@yahoo.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2022
• First Posted: December 5, 2022
• Study Start: January 25, 2022
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: December 5, 2022

Record last verified: 2021-12

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)